SCM
CTNM

Suvretta Capital Management’s Contineum Therapeutics CTNM Stock Holding History

Suvretta Capital Management’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37.1M Hold
2,841,334
– – 0.95% 37
2025
Q4 		$32.5M Buy
2,841,334
+1,121,334
+65% +$12.8M 0.67% 46
2025
Q3 		$20.2M Hold
1,720,000
– – 0.52% 54
2025
Q2 		$6.83M Hold
1,720,000
– – 0.21% 59
2025
Q1 		$12M Hold
1,720,000
– – 0.45% 53
2024
Q4 		$25.2M Hold
1,720,000
– – 0.86% 41
2024
Q3 		$32.9M Sell
1,720,000
-333,334
-16% -$6.39M 1.05% 36
2024
Q2 		$36.2M Buy
+2,053,334
New +$33.1M 1.33% 24

Other funds holding CTNM

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Suvretta Capital Management's CTNM Position: Q1 2026 in Review

Suvretta Capital Management held its Contineum Therapeutics (CTNM) position steady in Q1 2026 at 2,841,334 shares worth $37.1M. The position accounts for 0.95% of the portfolio, ranked #37.

Suvretta Capital Management first reported a position in CTNM in Q2 2024 and has held it in 8 quarters since. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • Suvretta Capital Management held 2,841,334 shares of Contineum Therapeutics worth $37.1M as of Q1 2026.
  • Suvretta Capital Management left its Contineum Therapeutics share count unchanged in Q1 2026.
  • Contineum Therapeutics made up 0.95% of Suvretta Capital Management's portfolio in Q1 2026, its #37 holding.
  • Suvretta Capital Management first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Suvretta Capital Management's 13F filing for Q1 2026, filed 15 May 2026.